Investigating the effect of Melatonin on the cognitive symptoms of patients with Schizophrenia treated with Risperidone: a randomized double-blind clinical trial

Ahvaz University of Medical Sciences0 个研究点目标入组 66 人开始时间: 待定最近更新: 2023年7月25日

适应症

试验速览

暂无简介。

•Patients admitted in the Psychiatric department of Ahvaz Golestan Hospital, who are in the age range of 16 to 65 years
•Diagnosis of schizophrenia based on DSM-5 criteria
•Informed consent of the patients or their guardian to participate in a research project
•Schizophrenic patients treated with risperidone

•Taking typical and atypical antipsychotic drugs, except for Risperidone, antidepressants, Sodium valproate, and Lithium.
•Presence of comorbid psychiatric disorder (bipolar-psychotic, obsessive-compulsive disorder, post-traumatic stress disorder, eating disorder)
•Current or past diagnosis (last 6 months) of severe personality disorders that compromise the participant's ability to meet the requirements.
•Use of narcotic drugs or alcohol in the last 12 months, except for nicotine and caffeine
•Presence of mental retardation or other neurological cognitive disorders such as dementia, delirium, head trauma, seizures, obstructive sleep apnea.
•History of ECT in the past 6 months
•In case of serious complications, the patient will be excluded from the study.
•Hypersensitivity to Melatonin or any of the ingredients in the placebo
•Use of Clozapine or previous use of Melatonin based on medical history obtained
•Pregnancy , lactating women
•Diagnosing the depressive episode of schizophrenia based on the Calgary questionnaire

发起方